ADA26: Oral PCSK9 inhibitor enlicitide delivers robust LDL-C lowering
Phase III data suggest oral PCSK9 inhibitor enlicitide delivers substantial LDL-C lowering without compromising glycemic control.
Phase III data suggest oral PCSK9 inhibitor enlicitide delivers substantial LDL-C lowering without compromising glycemic control.